Frahm Grant E, Smith Daryl G S, Kane Anita, Lorbetskie Barry, Cyr Terry D, Girard Michel, Johnston Michael J W
Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada.
PLoS One. 2014 Oct 9;9(10):e109893. doi: 10.1371/journal.pone.0109893. eCollection 2014.
The use of different expression systems to produce the same recombinant human protein can result in expression-dependent chemical modifications (CMs) leading to variability of structure, stability and immunogenicity. Of particular interest are recombinant human proteins expressed in plant-based systems, which have shown particularly high CM variability. In studies presented here, recombinant human serum albumins (rHSA) produced in Oryza sativa (Asian rice) (OsrHSA) from a number of suppliers have been extensively characterized and compared to plasma-derived HSA (pHSA) and rHSA expressed in yeast (Pichia pastoris and Saccharomyces cerevisiae). The heterogeneity of each sample was evaluated using size exclusion chromatography (SEC), reversed-phase high-performance liquid chromatography (RP-HPLC) and capillary electrophoresis (CE). Modifications of the samples were identified by liquid chromatography-mass spectrometry (LC-MS). The secondary and tertiary structure of the albumin samples were assessed with far U/V circular dichroism spectropolarimetry (far U/V CD) and fluorescence spectroscopy, respectively. Far U/V CD and fluorescence analyses were also used to assess thermal stability and drug binding. High molecular weight aggregates in OsrHSA samples were detected with SEC and supplier-to-supplier variability and, more critically, lot-to-lot variability in one manufactures supplied products were identified. LC-MS analysis identified a greater number of hexose-glycated arginine and lysine residues on OsrHSA compared to pHSA or rHSA expressed in yeast. This analysis also showed supplier-to-supplier and lot-to-lot variability in the degree of glycation at specific lysine and arginine residues for OsrHSA. Both the number of glycated residues and the degree of glycation correlated positively with the quantity of non-monomeric species and the chromatographic profiles of the samples. Tertiary structural changes were observed for most OsrHSA samples which correlated well with the degree of arginine/lysine glycation. The extensive glycation of OsrHSA from multiple suppliers may have further implications for the use of OsrHSA as a therapeutic product.
使用不同的表达系统来生产相同的重组人蛋白可能会导致依赖于表达的化学修饰(CMs),从而导致结构、稳定性和免疫原性的变异性。特别值得关注的是在基于植物的系统中表达的重组人蛋白,其显示出特别高的CM变异性。在本文介绍的研究中,对来自多个供应商的在水稻(亚洲稻)中产生的重组人血清白蛋白(rHSA)(OsrHSA)进行了广泛的表征,并与血浆来源的HSA(pHSA)和在酵母(毕赤酵母和酿酒酵母)中表达的rHSA进行了比较。使用尺寸排阻色谱法(SEC)、反相高效液相色谱法(RP-HPLC)和毛细管电泳法(CE)评估每个样品的异质性。通过液相色谱-质谱联用(LC-MS)鉴定样品的修饰。分别用远紫外圆二色光谱法(远紫外CD)和荧光光谱法评估白蛋白样品的二级和三级结构。远紫外CD和荧光分析也用于评估热稳定性和药物结合。用SEC检测到OsrHSA样品中的高分子量聚集体,并确定了供应商之间以及更关键的是一个制造商供应产品中批次之间的变异性。LC-MS分析表明,与pHSA或酵母中表达的rHSA相比,OsrHSA上有更多的己糖糖化精氨酸和赖氨酸残基。该分析还显示,OsrHSA在特定赖氨酸和精氨酸残基处的糖化程度存在供应商之间和批次之间的变异性。糖化残基的数量和糖化程度与非单体物种的数量和样品的色谱图谱呈正相关。观察到大多数OsrHSA样品的三级结构变化与精氨酸/赖氨酸糖化程度密切相关。来自多个供应商的OsrHSA的广泛糖化可能对将OsrHSA用作治疗产品有进一步的影响。